Design Therapeutics, Inc. (DSGN) vs Lexicon Pharmaceuticals, Inc. (LXRX)

Design Therapeutics, Inc. and Lexicon Pharmaceuticals, Inc. are both Biotechnology companies. Design Therapeutics, Inc. and Lexicon Pharmaceuticals, Inc. are of similar size ($854.3M and $809.3M). Design Therapeutics, Inc. has the higher net margin (0.00% vs −147.4%) and the higher return on invested capital (0.00% vs −96.4%). Across the 16 metrics below, Design Therapeutics, Inc. leads on 9 and Lexicon Pharmaceuticals, Inc. on 7.

Valuation

Metric DSGN LXRX Biotechnology median
P/E n/m n/m 7.88
P/S 3,363.10 19.00 11.47
P/B 3.77 4.51 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 2,445.42 15.75 10.73
Earnings yield (9.70%) (8.48%) (28.84%)
Free cash flow yield (7.27%) (8.38%) (23.03%)

Profitability

Metric DSGN LXRX Biotechnology median
Gross margin 0.00% 99.14% 65.16%
Operating margin 0.00% (131.43%) 0.00%
Net margin 0.00% (147.38%) 0.00%
Free cash flow margin 0.00% (156.71%) 0.00%
Return on equity (34.13%) (40.21%) (57.72%)
Return on assets (32.33%) (25.70%) (49.22%)
Return on invested capital 0.00% (96.36%) 0.00%

Growth

Metric DSGN LXRX Biotechnology median
Revenue growth (TTM) — (29.03%) 5.64%
EPS growth (last fiscal year) (38.64%) 77.78% —
Revenue growth, 5-year CAGR — 15.72% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric DSGN LXRX Biotechnology median
Debt to equity 0.00 0.29 0.00
Current ratio 18.86 13.37 4.73
Net debt to EBITDA 2.68 0.91 0.96

Dividend

Metric DSGN LXRX Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric DSGN LXRX Biotechnology median
Market cap 809.26m 854.32m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack